Nasdaq · CIK 0001501796
AURA Aura Biosciences, Inc.
Insider trading from SEC Form 4. Last filing 42 d ago. Close $6.54 on Oct 9, 2026, +32% from the 52-week low and -27% from the high.
Aura Biosciences, Inc. (AURA) has 58 SEC Form 4 filings on file from 16 insiders, the latest filed on Sep 1, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
32 open-market trades have been scored at AURA. The newest: Anthony S Gibney (See Remarks) sold $82k of stock on Jun 16, 2026, filed Jun 16, 2026, scored 24 (weak). The largest of the 32 shown: Matrix Capital Management Company, LP (10% owner) sold $39M on May 7, 2026, scored 57 (moderate). 5 insiders sold within 14 days of each other around Feb 17, 2026.
AURA closed at $6.54 on Oct 9, 2026, 32% above its 52-week low and 27% below its 52-week high.
21 Form 144 notices of planned sales are on file, the latest filed Nov 17, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
AURAOct 9, 2026 · close 6.54
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Aura Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | Anthony S Gibney See Remarks sell | $82k 12,824 shares | -5% | +26% from low-29% from high | |
| 57Moderate | Matrix Capital Management Company, LP owner sell | $39M 6,922,870 shares | -100% | +67% from low-8% from high | |
| 24Weak | Conor Kilroy See Remarks sell | $82k 11,738 shares | -5% | +44% from low-2% from high | |
| 48Moderate | Pinos Elisabet de los See Remarks sell | $241k 47,648 shares | -10% | +7% from low-31% from high | |
| 41Moderate | Amy Elazzouzi Senior Vice President, Finance sell | $43k 8,549 shares | -10% | +7% from low-31% from high | |
| 40Moderate | Janet Jill Hopkins Chief Medical Officer sell | $103k 20,401 shares | -8% | +7% from low-31% from high | |
| 39Weak | Mark Plavsic Chief Technology Officer sell | $80k 15,890 shares | -8% | +7% from low-31% from high | |
| 37Weak | Conor Kilroy See Remarks sell | $61k 12,079 shares | -7% | +7% from low-31% from high | |
| 32Weak | Pinos Elisabet de los See Remarks sell | $82k 16,928 shares | -4% | +1% from low-39% from high | |
| 23Weak | Amy Elazzouzi Senior Vice President, Finance sell | $7,684 1,581 shares | -2% | +1% from low-39% from high | |
| 25Weak | Janet Jill Hopkins Chief Medical Officer sell | $93k 17,109 shares | -6% | +12% from low-41% from high | |
| 37Weak | Pinos Elisabet de los See Remarks sell | $57k 9,049 shares | -2% | +25% from low-45% from high | |
| 30Weak | Amy Elazzouzi Senior Vice President, Finance sell | $5,690 896 shares | -1% | +25% from low-45% from high | |
| 38Weak | Mark Plavsic Chief Technology Officer sell | $77k 12,169 shares | -6% | +26% from low-47% from high | |
| 7Weak | Amy Elazzouzi Senior Vice President, Finance sell | $52k 7,722 shares | -8% | +37% from low-43% from high | |
| 54Moderate | Anthony S Gibney See Remarks buy | $245k 50,000 shares | +592% | +21% from low-49% from high | |
| 15Weak | Anthony S Gibney See Remarks sell | $7,823 1,519 shares | -3% | +21% from low-49% from high | |
| 44Moderate | David Michael Johnson director buy | $98k 20,000 shares | +14% | +21% from low-49% from high | |
| 29Weak | Conor Kilroy See Remarks sell | $39k 7,162 shares | -4% | +9% from low-54% from high | |
| 23Weak | Amy Elazzouzi Senior Vice President, Finance sell | $4,925 897 shares | -1% | +9% from low-54% from high | |
| 41Moderate | Pinos Elisabet de los See Remarks sell | $157k 20,221 shares | -4% | - | |
| 30Weak | Janet Jill Hopkins Chief Medical Officer sell | $20k 2,534 shares | -1% | - | |
| 30Weak | Amy Elazzouzi Senior Vice President, Finance sell | $11k 1,404 shares | -2% | - | |
| 30Weak | Mark Plavsic Chief Technology Officer sell | $17k 2,151 shares | -1% | - | |
| 23Weak | Amy Elazzouzi Vice President, Finance sell | $7,679 1,001 shares | -3% | - | |
| 33Weak | Pinos Elisabet de los See Remarks sell | $122k 15,955 shares | -5% | - | |
| 25Weak | Janet Jill Hopkins Chief Medical Officer sell | $111k 11,822 shares | -7% | - | |
| 30Weak | Amy Elazzouzi Vice President, Finance sell | $5,938 553 shares | -1% | - | |
| 40Moderate | Pinos Elisabet de los See Remarks sell | $99k 9,200 shares | -3% | - | |
| 21Weak | Julie B Feder Chief Financial Officer sell | $302k 25,131 shares | -16% | - | |
| 9Weak | Pinos Elisabet de los See Remarks sell | $301k 24,992 shares | -7% | - | |
| 38Weak | Mark Plavsic Chief Technology Officer sell | $73k 7,383 shares | -6% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 17, 2025 | Hopkins Janet Jill Officer | 17,109 0.03% of outstanding | $93k | Nov 17, 2025 | none |
| Oct 29, 2025 | de los Pinos Elisabet Officer, Director | 9,049 0.01% of outstanding | $57k | Oct 29, 2025 | none |
| Oct 29, 2025 | Elazzouzi Amy Officer | 896 0.00% of outstanding | $5,690 | Oct 29, 2025 | $52k |
| Oct 16, 2025 | Plavsic Mark Officer | 12,169 0.02% of outstanding | $77k | Oct 16, 2025 | none |
| Aug 18, 2025 | AMY F ELAZZOUZI Officer | 7,722 0.01% of outstanding | $52k | Aug 18, 2025 | none |
| May 16, 2025 | Gibney Anthony Officer | 1,519 0.00% of outstanding | $7,823 | May 16, 2025 | none |
| Apr 16, 2025 | Kilroy Conor Officer | 7,162 0.01% of outstanding | $39k | Apr 16, 2025 | none |
| Apr 16, 2025 | Elazzouzi Amy Officer | 897 0.00% of outstanding | $4,925 | Apr 16, 2025 | $19k |
| Feb 18, 2025 | de los Pinos Elisabet Officer, Director | 20,221 0.04% of outstanding | $157k | Feb 18, 2025 | $122k |
| Feb 18, 2025 | Elazzouzi Amy Officer | 1,404 0.00% of outstanding | $11k | Feb 18, 2025 | $7,679 |
| Feb 18, 2025 | Hopkins Janet Jill Officer | 2,534 0.01% of outstanding | $20k | Feb 18, 2025 | $111k |
| Feb 18, 2025 | Plavsic Mark Officer | 2,151 0.00% of outstanding | $17k | Feb 18, 2025 | none |
| Jan 21, 2025 | Elazzouzi Amy Officer | 1,001 0.00% of outstanding | $7,679 | Jan 21, 2025 | $5,938 |
| Jan 21, 2025 | de los Pinos Elisabet Officer, Director | 15,955 0.03% of outstanding | $122k | Jan 21, 2025 | $99k |
| Nov 18, 2024 | Janet Jill Hopkins Officer | 11,822 0.02% of outstanding | $111k | Nov 18, 2024 | none |
| Oct 29, 2024 | Julie B. Feder Former Officer | 3,249 0.01% of outstanding | $35k | Oct 29, 2024 | $216k |
| Oct 29, 2024 | Elisabet de los Pinos Officer, Director | 9,200 0.02% of outstanding | $99k | Oct 29, 2024 | $232k |
| Oct 29, 2024 | Amy Elazzouzi Officer | 553 0.00% of outstanding | $5,938 | Oct 29, 2024 | none |
| Oct 18, 2024 | ELISABET DE LOS PINOS Director, Officer | 24,992 0.05% of outstanding | $257k | Oct 18, 2024 | none |
| Oct 18, 2024 | JULIE FEDER Officer | 25,131 0.05% of outstanding | $259k | Oct 18, 2024 | none |
| Oct 16, 2024 | Plavsic Mark Officer | 7,383 0.01% of outstanding | $73k | Oct 16, 2024 | none |
Transactions
The newest 50 of 112 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Erica Kratz Chief Reg. & Quality Officer | AGrant or award Common Stock | +100,885 | $0.00 | $0 | 100,885 | 42 d ago |
| Sep 1, 2026 | Susan Abu-Absi Chief Operating Officer | AGrant or award Common Stock | +134,513 | $0.00 | $0 | 134,513 | 42 d ago |
| Sep 1, 2026 | Amy Elazzouzi SVP, Finance & PAO | AGrant or award Common Stock | +23,540 | $0.00 | $0 | 143,600 | 42 d ago |
| Sep 1, 2026 | Janet Jill Hopkins Chief Medical Officer | AGrant or award Common Stock | +58,850 | $0.00 | $0 | 380,190 | 42 d ago |
| Sep 1, 2026 | Julie Person Chief People Officer | AGrant or award Common Stock | +107,611 | $0.00 | $0 | 107,611 | 42 d ago |
| Sep 1, 2026 | Janet Jill Hopkins Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +116,150 | $0.00 | $0 | 116,150 | 42 d ago |
| Sep 1, 2026 | Amy Elazzouzi SVP, Finance & PAO | AGrant or award Stock Option (Right to Buy)derivative | +46,460 | $0.00 | $0 | 46,460 | 42 d ago |
| Sep 1, 2026 | Erica Kratz Chief Reg. & Quality Officer | AGrant or award Stock Option (Right to Buy)derivative | +199,115 | $0.00 | $0 | 199,115 | 42 d ago |
| Sep 1, 2026 | Julie Person Chief People Officer | AGrant or award Stock Option (Right to Buy)derivative | +212,389 | $0.00 | $0 | 212,389 | 42 d ago |
| Sep 1, 2026 | Susan Abu-Absi Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +265,487 | $0.00 | $0 | 265,487 | 42 d ago |
| Jun 16, 2026 | Anthony S Gibney See Remarks | SOpen-market sale Common Stock | -12,824 | $6.42 | $82k | 265,354 | Jun 16, 2026 |
| Jun 11, 2026 | Sapna Srivastava director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 38,500 | Jun 15, 2026 |
| Jun 11, 2026 | Teresa Marie Bitetti director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 36,000 | Jun 15, 2026 |
| Jun 11, 2026 | Antony C. Mattessich director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 38,500 | Jun 15, 2026 |
| Jun 11, 2026 | David Michael Johnson director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 194,167 | Jun 15, 2026 |
| Jun 11, 2026 | Sapna Srivastava director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 15, 2026 |
| Jun 11, 2026 | Teresa Marie Bitetti director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 15, 2026 |
| Jun 11, 2026 | Antony C. Mattessich director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 15, 2026 |
| Jun 11, 2026 | David Michael Johnson director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 15, 2026 |
| May 19, 2026 | Natalie C. Holles See Remarks | AGrant or award Common Stock | +600,118 | $0.00 | $0 | 600,118 | May 19, 2026 |
| May 19, 2026 | Natalie C. Holles See Remarks | AGrant or award Common Stock | +553,844 | $0.00 | $0 | 1,153,962 | May 19, 2026 |
| May 19, 2026 | Natalie C. Holles See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +2,169,103 | $0.00 | $0 | 2,169,103 | May 19, 2026 |
| May 7, 2026 | Matrix Capital Management Company, LP owner | SOpen-market sale Common Stock, par value $0.00001 per share (Common Stock)indirect: See footnotes | -6,922,870 | $5.64 | $39M | 0 | May 11, 2026 |
| Apr 16, 2026 | Conor Kilroy See Remarks | SOpen-market sale Common Stock | -11,738 | $7.02 | $82k | 217,835 | Apr 16, 2026 |
| Mar 2, 2026 | Anthony S Gibney See Remarks | AGrant or award Common Stock | +71,245 | $0.00 | $0 | 278,178 | Mar 3, 2026 |
| Mar 2, 2026 | Conor Kilroy See Remarks | AGrant or award Common Stock | +62,339 | $0.00 | $0 | 229,573 | Mar 3, 2026 |
| Mar 2, 2026 | Amy Elazzouzi Senior Vice President, Finance | AGrant or award Common Stock | +44,528 | $0.00 | $0 | 120,060 | Mar 3, 2026 |
| Mar 2, 2026 | Janet Jill Hopkins Chief Medical Officer | AGrant or award Common Stock | +89,056 | $0.00 | $0 | 321,340 | Mar 3, 2026 |
| Mar 2, 2026 | Mark Plavsic Chief Technology Officer | AGrant or award Common Stock | +62,339 | $0.00 | $0 | 243,736 | Mar 3, 2026 |
| Mar 2, 2026 | Pinos Elisabet de los See Remarks | AGrant or award Common Stock | +166,000 | $0.00 | $0 | 575,815 | Mar 3, 2026 |
| Mar 2, 2026 | Anthony S Gibney See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +128,755 | $0.00 | $0 | 128,755 | Mar 3, 2026 |
| Mar 2, 2026 | Conor Kilroy See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +112,661 | $0.00 | $0 | 112,661 | Mar 3, 2026 |
| Mar 2, 2026 | Amy Elazzouzi Senior Vice President, Finance | AGrant or award Stock Option (Right to Buy)derivative | +80,472 | $0.00 | $0 | 80,472 | Mar 3, 2026 |
| Mar 2, 2026 | Janet Jill Hopkins Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +160,944 | $0.00 | $0 | 160,944 | Mar 3, 2026 |
| Mar 2, 2026 | Mark Plavsic Chief Technology Officer | AGrant or award Stock Option (Right to Buy)derivative | +112,661 | $0.00 | $0 | 112,661 | Mar 3, 2026 |
| Mar 2, 2026 | Pinos Elisabet de los See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +249,000 | $0.00 | $0 | 249,000 | Mar 3, 2026 |
| Feb 17, 2026 | Pinos Elisabet de los See Remarks | SOpen-market sale Common Stock | -47,648 | $5.06 | $241k | 409,815 | Feb 17, 2026 |
| Feb 17, 2026 | Amy Elazzouzi Senior Vice President, Finance | SOpen-market sale Common Stock | -8,549 | $5.06 | $43k | 75,532 | Feb 17, 2026 |
| Feb 17, 2026 | Janet Jill Hopkins Chief Medical Officer | SOpen-market sale Common Stock | -20,401 | $5.06 | $103k | 232,284 | Feb 17, 2026 |
| Feb 17, 2026 | Mark Plavsic Chief Technology Officer | SOpen-market sale Common Stock | -15,890 | $5.05 | $80k | 181,397 | Feb 17, 2026 |
| Feb 17, 2026 | Conor Kilroy See Remarks | SOpen-market sale Common Stock | -12,079 | $5.05 | $61k | 167,234 | Feb 17, 2026 |
| Jan 20, 2026 | Pinos Elisabet de los See Remarks | SOpen-market sale Common Stock | -16,928 | $4.86 | $82k | 457,463 | Jan 20, 2026 |
| Jan 20, 2026 | Amy Elazzouzi Senior Vice President, Finance | SOpen-market sale Common Stock | -1,581 | $4.86 | $7,684 | 84,081 | Jan 20, 2026 |
| Nov 17, 2025 | Janet Jill Hopkins Chief Medical Officer | SOpen-market sale Common Stock | -17,109 | $5.42 | $93k | 252,685 | Nov 17, 2025 |
| Oct 29, 2025 | Pinos Elisabet de los See Remarks | SOpen-market sale Common Stock | -9,049 | $6.35 | $57k | 474,391 | Oct 29, 2025 |
| Oct 29, 2025 | Amy Elazzouzi Senior Vice President, Finance | SOpen-market sale Common Stock | -896 | $6.35 | $5,690 | 85,662 | Oct 29, 2025 |
| Oct 16, 2025 | Mark Plavsic Chief Technology Officer | SOpen-market sale Common Stock | -12,169 | $6.35 | $77k | 197,287 | Oct 16, 2025 |
| Aug 18, 2025 | Amy Elazzouzi Senior Vice President, Finance | MOption exercise Common Stock | +2,554 | $5.07 | $13k | 83,935 | Aug 18, 2025 |
| Aug 18, 2025 | Amy Elazzouzi Senior Vice President, Finance | MOption exercise Common Stock | +1,094 | $5.48 | $5,995 | 85,029 | Aug 18, 2025 |
| Aug 18, 2025 | Amy Elazzouzi Senior Vice President, Finance | MOption exercise Common Stock | +547 | $5.48 | $2,998 | 85,576 | Aug 18, 2025 |
50 of 112 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Susan Abu-AbsiChief Operating Officer
- Teresa Marie Bitettidirector, president, officer
- Amy ElazzouziSenior Vice President, Finance
- Julie B FederChief Financial Officer
- Anthony S GibneySee Remarks
- Natalie C. HollesSee Remarks
- Janet Jill HopkinsChief Medical Officer
- David Michael Johnsondirector
- Conor KilroySee Remarks
- Erica KratzChief Reg. & Quality Officer
- Matrix Capital Management Company, LPowner
- Antony C. Mattessichdirector
- Julie PersonChief People Officer
- Mark PlavsicChief Technology Officer
- Sapna Srivastavadirector
- Pinos Elisabet de losSee Remarks
Questions about AURA
Answered from the filings on this page, as of the latest one.
Are insiders buying AURA?
No. In the last 90 days no insider at Aura Biosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AURA on the open market?
Anthony S Gibney (See Remarks) sold $82k of AURA on Jun 16, 2026 and filed the Form 4 on Jun 16, 2026. InsiderTell scored 24 (weak).
How many insiders file Form 4 at Aura Biosciences, Inc.?
16 people have filed a Form 4 at Aura Biosciences, Inc., among them Susan Abu-Absi (Chief Operating Officer), Teresa Marie Bitetti (director and president), Amy Elazzouzi (Senior Vice President, Finance). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.